Provided by Tiger Fintech (Singapore) Pte. Ltd.

IO Biotech, Inc.

0.9850
-0.0850-7.94%
Volume:65.29K
Turnover:66.29K
Market Cap:64.89M
PE:-0.68
High:1.10
Open:1.10
Low:0.9770
Close:1.07
Loading ...

Company Profile

Company Name:
IO Biotech, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
80
Office Location:
Ole MaalOees Vej 3,Copenhagen N,Copenhagen,Capital Region of Denmark,Denmark
Zip Code:
2200
Fax:
- -
Introduction:
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Directors

Name
Position
Mai Britt Zocca
Chief Executive Officer and Director
Peter Hirth
Chairman of the Board
Christian Elling
Director
Claus Andersson
Director
Emmanuelle Coutanceau
Director
Jack B. Nielsen
Director
Kathleen Sereda Glaub
Director
Priyanka Belawat
Director
Vanessa Malier
Director

Shareholders

Name
Position
Mai Britt Zocca
Chief Executive Officer and Director
Keith Vendola
Chief Financial Officer
Eva Ehrnrooth
Chief Medical Officer
Muhammad Al Hajj
Chief Scientific Officer